DYNAVAX TECHNOLOGIES CORP's ticker is DVAX and the CUSIP is 268158201. A total of 153 filers reported holding DYNAVAX TECHNOLOGIES CORP in Q3 2018. The put-call ratio across all filers is 1.70 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $35,330,000 | -59.7% | 2,316,674 | -47.6% | 0.42% | -59.6% |
| Q1 2018 | $87,770,000 | -20.9% | 4,421,674 | -25.5% | 1.05% | -7.0% |
| Q4 2017 | $110,990,000 | -15.6% | 5,935,274 | -2.9% | 1.13% | -16.6% |
| Q3 2017 | $131,470,000 | +346.4% | 6,114,874 | +103.5% | 1.36% | +114.9% |
| Q2 2017 | $29,450,000 | +111.1% | 3,005,137 | +28.2% | 0.63% | +114.2% |
| Q1 2017 | $13,950,000 | +399.5% | 2,344,500 | +231.5% | 0.30% | +408.6% |
| Q4 2016 | $2,793,000 | – | 707,200 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chicago Capital, LLC | 5,791,735 | $85,543,929 | 4.00% |
| Deep Track Capital, LP | 6,756,956 | $99,800,240 | 3.85% |
| Intrinsic Edge Capital Management LLC | 1,133,099 | $16,735,872 | 1.89% |
| Bain Capital Life Sciences Investors, LLC | 915,000 | $13,514,550 | 1.51% |
| Kynam Capital Management, LP | 500,000 | $7,385,000 | 1.21% |
| Rhenman & Partners Asset Management AB | 700,000 | $10,339,000 | 1.12% |
| AlphaCentric Advisors LLC | 110,000 | $1,624,700 | 0.92% |
| HighVista Strategies LLC | 133,000 | $1,964,410 | 0.91% |
| Affinity Asset Advisors, LLC | 200,000 | $2,954,000 | 0.83% |
| Rock Springs Capital Management LP | 1,813,758 | $26,789,206 | 0.72% |